Payment overview · 2025
General Payments
$1,326.13
73 reported records · 14 companies
Healthcare provider profile · identity verified
Robert Jarod Steckmeyer, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MONROE, MI · NPI 1104194638
Verified facts
What the public records show
CMS Open Payments records show Robert Jarod Steckmeyer, FNP-BC received $1,326.13 in general payments during 2025 across 73 reported records.
ABBVIE INC. accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $256.06 | 19.3% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.34 | 16.0% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $195.48 | 14.7% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $190.63 | 14.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $104.44 | 7.9% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $96.49 | 7.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.53 | 4.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.91 | 3.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.49 | 3.9% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $31.50 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.89 | 1.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.17 | 1.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.3% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,326.13 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $251.21 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $190.63 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.67 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $116.52 | 6 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $103.53 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $91.95 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.04 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.67 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $66.94 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $62.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.43 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $4.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $4.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 100 |
| Lisinopril | Lisinopril | 250 | 64 |
| Omeprazole | Omeprazole | 221 | 62 |
| Metformin Hcl | Metformin Hcl | 193 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 54 |
| Gabapentin | Gabapentin | 146 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 51 |
| Glipizide Er | Glipizide | 129 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 43 |
| Furosemide | Furosemide | 112 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 27 |
| Ibuprofen | Ibuprofen | 92 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 18 |
| Sertraline Hcl | Sertraline Hcl | 83 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 22 |
| Carvedilol | Carvedilol | 81 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 18 |
| Meloxicam | Meloxicam | 71 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 17 |
| Losartan Potassium | Losartan Potassium | 68 | 21 |
| Trazodone Hcl | Trazodone Hcl | 66 | 20 |
| Ozempic | Semaglutide | 65 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 22 |
| Potassium Chloride | Potassium Chloride | 57 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 19 |
| Naproxen | Naproxen | 50 | suppressed |
| Simvastatin | Simvastatin | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 13 |
| Jardiance | Empagliflozin | 42 | 12 |
| Glipizide | Glipizide | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 15 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Nystatin | Nystatin | 29 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Tri-Lo-Estarylla | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,326.13 · 73 records | ABBVIE INC. | ABRYSVO, AUSTEDO XR, Auvelity, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OPSUMIT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, SUBLOCADE, The Cologuard Plus Collection Kit, UPTRAVI, UZEDY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error